176 related articles for article (PubMed ID: 36669148)
21. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group.
Kopp LM; Womer RB; Schwartz CL; Ebb DH; Franco VI; Hall D; Barkauskas DA; Krailo MD; Grier HE; Meyers PA; Wexler LH; Marina NM; Janeway KA; Gorlick R; Bernstein ML; Lipshultz SE;
Cardiooncology; 2019; 5():15. PubMed ID: 32154021
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
[TBL] [Abstract][Full Text] [Related]
23. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB; Colan SD; Neuberg DS; Dahlberg SE; Henkel JM; Asselin BL; Athale UH; Clavell LA; Laverdière C; Michon B; Schorin MA; Sallan SE
J Clin Oncol; 2012 Apr; 30(10):1042-9. PubMed ID: 22370326
[TBL] [Abstract][Full Text] [Related]
24. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors.
Caru M; Corbin D; Périé D; Lemay V; Delfrate J; Drouin S; Bertout L; Krajinovic M; Laverdière C; Andelfinger G; Sinnett D; Curnier D
Clin Res Cardiol; 2019 Sep; 108(9):1000-1008. PubMed ID: 30778669
[TBL] [Abstract][Full Text] [Related]
27. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
Paiva MG; Petrilli AS; Moisés VA; Macedo CR; Tanaka C; Campos O
Pediatr Blood Cancer; 2005 Dec; 45(7):902-8. PubMed ID: 16035077
[TBL] [Abstract][Full Text] [Related]
28. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
29. Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with Dexrazoxane-Anthracyclines association.
Filomena D; Versacci P; Cimino S; Mattiucci C; Maestrini V; Cantisani D; Petronilli V; Agati L; Schiavetti A
Int J Cardiol; 2020 Jan; 299():271-275. PubMed ID: 31422879
[TBL] [Abstract][Full Text] [Related]
30. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial.
Armenian SH; Hudson MM; Lindenfeld L; Chen S; Chow EJ; Colan S; Collier W; Su X; Marcus E; Echevarria M; Iukuridze A; Robison LL; Wong FL; Chen MH; Bhatia S
Lancet Oncol; 2024 Feb; 25(2):235-245. PubMed ID: 38215764
[TBL] [Abstract][Full Text] [Related]
31. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.
Ganatra S; Nohria A; Shah S; Groarke JD; Sharma A; Venesy D; Patten R; Gunturu K; Zarwan C; Neilan TG; Barac A; Hayek SS; Dani S; Solanki S; Mahmood SS; Lipshultz SE
Cardiooncology; 2019; 5():1. PubMed ID: 32154008
[TBL] [Abstract][Full Text] [Related]
32. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
[TBL] [Abstract][Full Text] [Related]
33. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
Choi HS; Park ES; Kang HJ; Shin HY; Noh CI; Yun YS; Ahn HS; Choi JY
J Korean Med Sci; 2010 Sep; 25(9):1336-42. PubMed ID: 20808678
[TBL] [Abstract][Full Text] [Related]
34. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
[TBL] [Abstract][Full Text] [Related]
35. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion.
Huh WW; Jaffe N; Durand JB; Munsell MF; Herzog CE
Pediatr Hematol Oncol; 2010 Oct; 27(7):546-57. PubMed ID: 20795769
[TBL] [Abstract][Full Text] [Related]
36. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
Lipshultz SE; Colan SD; Gelber RD; Perez-Atayde AR; Sallan SE; Sanders SP
N Engl J Med; 1991 Mar; 324(12):808-15. PubMed ID: 1997853
[TBL] [Abstract][Full Text] [Related]
37. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
38. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
39. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
Sparano JA; Speyer J; Gradishar WJ; Liebes L; Sridhara R; Mendoza S; Fry D; Egorin MJ
J Clin Oncol; 1999 Mar; 17(3):880-6. PubMed ID: 10071279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
